ALKBH5 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, featuring targeted disruption of the ALKBH5 gene. This heterogeneous pool of edited cells provides a robust loss-of-function model for studying the m6A RNA demethylase ALKBH5 in lung cancer, avoiding clonal bias and better representing the complex genetic landscape of tumor cell populations.
The parental A-549 cell line is a human lung adenocarcinoma epithelial model isolated from a 58-year-old male. It is widely used to study non-small cell lung cancer biology, including oncogenic signaling, tumorigenesis, drug response, and respiratory epithelial cell function, making it a relevant host for interrogating ALKBH5-dependent epitranscriptomic mechanisms in a clinically meaningful context.
ALKBH5 is an m6A RNA demethylase that oxidatively reverses methylation installed by the METTL3/METTL14/WTAP complex, thereby regulating mRNA stability, splicing, and translation. Its expression is controlled by transcription factors such as HIF-1??, c-MYC, p53, FOXM1, and SP1, connecting it to hypoxia, cell cycle, and oncogenic pathways. ALKBH5 demethylates target transcripts including FOXM1, NANOG, KLF4, SOCS2, and EGFR, influencing stemness, proliferation, and signal transduction. It interacts with m6A reader proteins (YTHDF2, IGF2BP1) and other demethylases like FTO to shape the cellular epitranscriptome.
In A-549 cells, ALKBH5 knockout leads to hypermethylation of its mRNA targets, impairing proliferation, migration, and tumorigenic capacity. This model captures the oncogenic role of ALKBH5 in lung adenocarcinoma and allows dissection of m6A-dependent regulation of pathways including p53 and MAPK/ERK. It is particularly suited for studying the interplay between RNA modifications and hypoxia-driven tumor adaptation, as well as ALKBH5-mediated control of stem cell factors such as NANOG and KLF4.
Research applications include transcriptome-wide m6A profiling (MeRIP-seq), RNA-seq, RT-qPCR validation of target genes, and functional assays such as MTS/CCK8, colony formation, apoptosis measurement, and migration/invasion tests. The cells support co-IP studies of m6A reader interactions and drug target validation for ALKBH5 inhibitors. This polyclonal knockout is a versatile tool for cancer epitranscriptomics and hypoxia research. For further information, please contact Ascent Research.
